Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/6/2008 First Published: 8/18/2006


1.		Phase III Randomized Study of Glutamic Acid in Reducing Vincristine-Related Peripheral Neurotoxicity in Young Patients Undergoing Vincristine-Containing Treatment for Wilms' Tumor, Rhabdomyosarcoma, Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				3 to 20				NCI				MCC-0402 NCT00369564, ACCL 0731

Last Modified: 5/23/2007


2.		Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Not specified				Other				MSKCC-95024 NCI-V95-0685, NCT00002663

Last Modified: 9/29/2008 First Published: 2/26/2008


3.		Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				Other				BCM-H-19386 BCM-FAB, H 19386, NCT00625144


4.		Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				0 to 55				Other				8717 NCT00673114

Last Modified: 8/28/2008


5.		Phase II Study of Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With Rituximab and Filgrastim (G-CSF) in Patients With Stage I-IV Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over for Burkitt's lymphoma				NCI				NCI-93-C-0133 CRB-9307, NCI-MB-303, NCI-T93-0023N, T93-0023, NCT00018980

Last Modified: 10/17/2008 First Published: 3/24/2003


6.		Phase II Pilot Study of Rituximab Added to the Induction and Consolidation Phases and Rasburicase Added to the Reduction Phase in Children With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma Treated With LMB/FAB Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				1 to 29				NCI				COG-ANHL01P1 NCT00057811, ANHL01P1

Last Modified: 5/28/2008 First Published: 3/24/2006


7.		Phase II Study of Myeloablative Preparative Regimen Comprising Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Patients Undergoing Unrelated Umbilical Cord Blood Transplantation for Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				45 and under				NCI				UMN-2005LS043 UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842

Last Modified: 1/4/2008 First Published: 6/22/2006


8.		Phase II Study of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin's or Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Under 70				NCI				UMN-2005LS048 UMN-0508M72589, UMN-MT2004-24, NCT00345865


9.		Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 to 60				Other				2005-0054 NCT00290498

Last Modified: 5/22/2008 First Published: 5/4/2007


10.		Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				Any age				NCI				CINJ-3330 NCT00161187

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute